CUTISS key facts
as of Oct 2026- Developer of customized bio-engineered skin grafts designed to treat large skin defects.
- CUTISS is valued at approximately $214.5M as of Oct 2026 (last reported valuation).
- It has raised $139.5M; the latest was Later Stage VC ($69.7M) in Sep 2025.
- Notable investors include Innosuisse, Zürcher Kantonalbank, Venture (Switzerland), GG 1978, ETH Zürich Foundation — 16 tracked in total.
- Status: Privately Held (backing).
CUTISS's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch CUTISS: the Monday email on marks, rounds and moves
CUTISS funding rounds
No funding rounds for CUTISS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs CUTISS
16+CUTISS valuation
CUTISS's last reported valuation was $215 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
CUTISS investors
16 investors are on record for CUTISS, including Innosuisse, Zürcher Kantonalbank, Venture (Switzerland) and GG 1978.
About CUTISS
Developer of customized bio-engineered skin grafts designed to treat large skin defects. The company's customized skin grafts use patients' cells in combination with a hydrogel to create dermo-epidermal skin and considerably reduce the need for autografting and further corrective interventions, allowing for considerable savings, enabling patients to get treated for affected or damaged skin.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2015
- Employees
- 50
- Website
- cutiss.swiss/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.